Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302’s potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
